| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
NBI-35965 mesylate targets the corticotropin-releasing factor-1 (CRF1) receptor. CRF1 receptors are G protein-coupled receptors that mediate the effects of corticotropin-releasing factor on the hypothalamic-pituitary-adrenal axis and on extrahypothalamic brain regions involved in stress and emotion. By blocking CRF1 receptors, NBI-35965 mesylate reduces CRF-induced ACTH release and attenuates stress-related behaviors.
|
|---|---|
| ln Vitro |
In vitro activity data for NBI-35965 mesylate demonstrate its high affinity for CRF1 receptors with a Ki of 4 nM and a pKi of 8.5. It acts as a competitive antagonist, blocking CRF-induced cAMP accumulation in cells expressing CRF1 receptors. The compound shows selectivity for CRF1 over CRF2 receptors, establishing its potency and selectivity as a CRF1 antagonist.
|
| ln Vivo |
In vivo studies have demonstrated that NBI-35965 mesylate reduces endocrine responses to CRF1 receptor-mediated pharmacological and behavioral challenges. It is orally active and brain-penetrant, allowing for systemic administration in animal models. The compound has been investigated for the treatment of stress disorders, anxiety, and depression in preclinical studies.
|
| Enzyme Assay |
For non-cell receptor binding assays, membranes are prepared from cells expressing recombinant human CRF1 receptors. Radiolabeled CRF or urocortin is used in competition binding assays with NBI-35965 mesylate. Ki values are determined from dose-response curves.
|
| Cell Assay |
For cell-based assays, cells expressing CRF1 receptors are treated with NBI-35965 mesylate, and cAMP accumulation is measured by ELISA or radioimmunoassay. Antagonist activity is assessed by reversal of CRF-induced cAMP stimulation.
|
| Animal Protocol |
For in vivo studies, rodent models of stress and anxiety, such as the elevated plus maze, forced swim test, or social defeat stress, are used. NBI-35965 mesylate is administered by oral or intraperitoneal routes at doses determined from pharmacokinetic studies. ACTH and corticosterone levels are measured by radioimmunoassay or ELISA.
|
| References |
|
| Molecular Formula |
C22H26CL2N4O3S
|
|---|---|
| Molecular Weight |
497.43
|
| Exact Mass |
436.099
|
| CAS # |
603151-83-3
|
| Related CAS # |
NBI 35965 hydrochloride; 1782228-59-4
|
| PubChem CID |
11713006
|
| Appearance |
White to off-white solid
|
| LogP |
6.589
|
| tPSA |
33.95
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
32
|
| Complexity |
637
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
Cl.CC[C@H]1CN2C3C(C(C4=CC=C(Cl)C=C4Cl)=N2)=NC(=CC=3N1CC1CC1)C
|
| InChi Key |
ARENHXRYYRAMQA-RSAXXLAASA-N
|
| InChi Code |
InChI=1S/C21H22Cl2N4.CH4O3S/c1-3-15-11-27-21-18(26(15)10-13-4-5-13)8-12(2)24-20(21)19(25-27)16-7-6-14(22)9-17(16)23;1-5(2,3)4/h6-9,13,15H,3-5,10-11H2,1-2H3;1H3,(H,2,3,4)/t15-;/m0./s1
|
| Chemical Name |
(10S)-9-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-10-ethyl-6-methyl-1,2,5,9-tetrazatricyclo[6.3.1.04,12]dodeca-2,4,6,8(12)-tetraene;methanesulfonic acid
|
| Synonyms |
NBI35965 Mesylate; NBI 35965 Mesylate; NBI-35965 Mesylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0103 mL | 10.0517 mL | 20.1033 mL | |
| 5 mM | 0.4021 mL | 2.0103 mL | 4.0207 mL | |
| 10 mM | 0.2010 mL | 1.0052 mL | 2.0103 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.